Drug intelligence / Profile preview

CB02

Development stage: Unknown
Lead developer: Cartography Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CB02 is a monoclonal antibody that recognizes a specific surface molecule found on B lymphocytes and a subset of CD16+ large granular lymphocytes, including natural killer (NK) cells. This surface molecule is expressed by B cells before isotype switch and is lost during terminal differentiation. The antibody's recognition of this molecule is associated with NK cell cytotoxic activity.

Beyond the preview

Go deeper on CB02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB02.

Explore the full profile